Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report
{{output}}
Osimertinib is a key drug for cancer patients with EGFR mutations. However, there is little information about its safety in cancer patients who require hemodialysis (HD) for chronic renal failure, despite notable increases in their numbers. Herein, we examined... ...
